Armata Pharmaceuticals (ARMP) Profit After Tax (2013 - 2026)

Armata Pharmaceuticals has reported Profit After Tax for 14 years, with the latest figure at -$115.3 million in Q1 2026.

• Quarterly Profit After Tax fell 1666.13% year-over-year to -$115.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$282.6 million (down 1086.31% YoY) and the FY2025 annual result came in at -$173.8 million, down 818.79% from the prior year.
• Profit After Tax grew to -$115.3 million in Q1 2026 per ARMP's latest filing, from -$124.3 million in the prior quarter.
• Over five years, Profit After Tax peaked at $2.6 million in Q4 2024 and troughed at -$124.3 million in Q4 2025.
• A 5-year average of -$25.7 million and a median of -$14.4 million in 2024 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2024 and 2025: Profit After Tax soared 113.1% in 2024, then slumped 4880.69% in 2025.
• Over 5 years, Profit After Tax stood at -$10.3 million in 2022, then tumbled by 92.43% to -$19.8 million in 2023, then jumped by 113.1% to $2.6 million in 2024, then plunged by 4880.69% to -$124.3 million in 2025, then rose by 7.2% to -$115.3 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$115.3 million, -$124.3 million, and -$26.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.